SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Falkinham J III. Nontuberculous mycobacteria in the environment. Clin. Chest Med. 2002; 23: 52952.
  • 2
    Marras T, Daley C. Epidemiology of human pulmonary infection with nontuberculous mycobacteria. Clin. Chest Med. 2002; 23: 55367.
  • 3
    Henry MT, Inamdar L, O'Riordain D, Schweiger M, Watson JP. Nontuberculous mycobacteria in non-HIV patients: epidemiology, treatment and response. Eur. Respir. J. 2004; 23: 7416.
  • 4
    Marras TK, Chedore P, Ying AM, Jamieson F. Isolation prevalence of pulmonary non-tuberculous mycobacteria in Ontario, 1997–2003. Thorax 2007; 62: 6616.
  • 5
    Fujita J, Ohtsuki Y, Suemitsu I, Shigeto E, Yamadori I et al. Pathological and radiological changes in resected lung specimens in Mycobacterium avium-intracellulare complex disease. Eur. Respir. J. 1999; 13: 53540.
  • 6
    Khan K, Wang J, Marras TK. Nontuberculous mycobacterial sensitization in the United States: national trends over three decades. Am. J. Respir. Crit. Care Med. 2007; 176: 30613.
  • 7
    Haverkort F, Australian Mycobacterium Reference Laboratory Network. National atypical mycobacteria survey, 2000. Commun. Dis. Intell. 2003; 27: 1809.
  • 8
    Thomsen V, Andersen A, Miorner H. Incidence and clinical significance of non-tuberculous mycobacteria isolated from clinical specimens during a 2 year nationwide survey. Scand. J. Infect. Dis. 2002; 34: 64853.
  • 9
    Martín-Casabona N, Bahrmand AR, Bennedsen J, Thomsen VØ, Curcio M et al. Non-tuberculous mycobacteria: patterns of isolation. A multi-country retrospective survey. Int. J. Tuberc. Lung Dis. 2004; 8:118693.
  • 10
    Maliwan N, Zvetina J. Clinical features and follow up of 302 patients with Mycobacterium kansasii pulmonary infection: a 50 year experience. Postgrad. Med. J. 2005; 81: 5303.
  • 11
    Costrini A, Mahler D, Gross W, Hawkins J, Yesner R et al. Clinical and roentgenographic features of nosocomial pulmonary disease due to Mycobacterium xenopi. Am. Rev. Respir. Dis. 1981; 123: 1049.
  • 12
    The Research Committee of the British Thoracic Society. Pulmonary disease caused by M. malmoense in HIV negative patients: 5-yr follow-up of patients receiving standardised treatment. Eur. Respir. J. 2003; 21: 47882.
  • 13
    Griffith D, Girard W, Wallace R Jr. Clinical features of pulmonary disease caused by rapidly growing mycobacteria: an analysis of 154 patients. Am. Rev. Respir. Dis. 1993; 147: 121718.
  • 14
    Iseman M, Buschman D, Ackerson L. Pectus excavatum and scoliosis: thoracic abnormalities associated with pulmonary disease caused by Mycobacterium avium complex. Am. Rev. Respir. Dis. 1991; 144: 91416.
  • 15
    Kwon Y, Koh W, Kwon OJ, Lee N, Han J et al. Mycobacterium abscessus pulmonary infection presenting as a solitary pulmonary nodule. Intern. Med. 2006; 45: 16971.
  • 16
    Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y et al. Four cases of pulmonary Mycobacterium avium intracellulare complex presenting as a solitary pulmonary nodule and a review of other cases in Japan. Respirology 2006; 11: 31721.
  • 17
    Gribetz A, Damsker B, Bottone E, Kirschner P, Teirstein A. Solitary pulmonary nodules due to nontuberculous mycobacterial infection. Am. J. Med. 1981; 70: 3943.
  • 18
    Embil J, Warren P, Yakrus M, Stark R, Corne S et al. Pulmonary illness associated with exposure to Mycobacterium-avium complex in hot tub water. Hypersensitivity pneumonitis or infection? Chest 1997; 111: 813.
  • 19
    Khoor A, Leslie K, Tazelaar H, Helmers R, Colby T. Diffuse pulmonary disease caused by nontuberculous mycobacteria in immunocompetent people (hot tub lung). Am. J. Clin. Pathol. 2001; 115: 75562.
  • 20
    Bernstein D, Lummus Z, Santilli G, Siskorsky J, Berstein I. Machine operator's lung, a hypersensitivity pneumonitis disorder associated with exposure to metalworking fluid aerosols. Chest 1995; 108: 63641.
  • 21
    Centers for Disease Control and Prevention. Respiratory illness in workers exposed to metalworking fluid contaminated with nontuberculous mycobacteria—Ohio, 2001. MMWR 2002; 51: 34952.
  • 22
    Olivier KN, Weber DJ, Wallace RJ Jr, Faiz AR, Lee J-H et al. Nontuberculous mycobacteria: I: multicenter prevalence study in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2003; 167: 82834.
  • 23
    Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007; 131: 116672.
  • 24
    Kunst H, Wickremasinghe M, Wells A, Wilson R. Nontuberculous mycobacterial disease and Aspergillus-related lung disease in bronchiectasis. Eur. Respir. J. 2006; 28: 3527.
  • 25
    Jeong Y, Lee K, Koh W, Han J, Kim T et al. Nontuberculous mycobacterial pulmonary infection in immunocompetent patients: comparison of thin section CT and histopathologic findings. Radiology 2004; 231: 8806.
  • 26
    Koh W-J, Lee KS, Kwon OJ, Jeong YJ, Kwak S-H et al. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology 2005; 235: 2828.
  • 27
    Reich J, Johnson R. Mycobacterium avium complex pulmonary disease presenting as an isolated lingular or middle lobe pattern. The Lady Windermere syndrome. Chest 1992; 101: 16059.
  • 28
    Obayashi Y, Fujii N, Suemitsu I, Kamei T, Takahara MN et al. Successive follow-up of chest computed tomography in patients with Mycobacterium avium-intracellulare complex. Respir. Med. 1999; 93: 1115.
  • 29
    Tanaka D, Niwatsukino H, Oyama T, Nakajo M. Progressing features of atypical mycobacterial infection in the lung on conventional and high resolution CT (HRCT) images. Radiat. Med. 2001; 19: 23745.
  • 30
    Hartman TE, Jensen E, Tazelaar HD, Hanak V, Ryu JH. CT findings of granulomatous pneumonitis secondary to Mycobacterium avium-intracellulare inhalation: ‘hot tub lung’. Am. J. Roentgenol. 2007; 188: 10503.
  • 31
    Runyon E. Typical mycobacteria: their classification. Am. Rev. Respir. Dis. 1965; 91: 2889.
  • 32
    Leitritz L, Schubert S, Bucherl B, Masch A, Heesemann J et al. Evaluation of BACTEC MGIT 960 and BACTEC 460TB systems for recovery of mycobacteria from clinical specimens of a university hospital with low incidence of tuberculosis. J. Clin. Microbiol. 2001; 39: 37647.
  • 33
    American Thoracic Society. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 1997; 156: S125.
  • 34
    Wilton S, Cousins D. Detection and identification of multiple mycobacterial pathogens by DNA amplification in a single tube. PCR Methods Appl. 1992; 4: 26973.
  • 35
    Cloud JL, Neal H, Rosenberry R, Turenne CY, Jama M et al. Identification of Mycobacterium spp. by using a commercial 16S ribosomal DNA sequencing kit and additional sequencing libraries. J. Clin. Microbiol. 2002; 40: 4006.
  • 36
    Cloud JL, Hoggan K, Belousov E, Cohen S, Brown-Elliott BA et al. Use of the MGB eclipse system and SmartCycler PCR for differentiation of Mycobacterium chelonae and M. abscessus. J. Clin. Microbiol. 2005; 43: 42057.
  • 37
    Griffith DE, Aksamit T, Brown-Elliott BA, Catanzaro A, Daley C et al. An Official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am. J. Respir. Crit. Care Med. 2007; 175: 367416.
  • 38
    Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob. Agents Chemother. 1996; 40: 175967.
  • 39
    Banks J, Jenkins P. Combined versus single antituberculous drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria. Thorax 1987; 42: 83842.
  • 40
    Horsburgh C Jr, Mason U 3rd, Heifets L. Response to therapy of pulmonary Mycobacterium avium-intracellulare infection correlates with results of in vitro susceptibility testing. Am. Rev. Respir. Dis. 1987; 135: 41821.
  • 41
    Tsukamura M. Evidence that antituberculosis drugs are really effective in the treatment of pulmonary infection caused by Mycobacterium avium complex. Am. Rev. Respir. Dis. 1988; 137: 1448.
  • 42
    The Research Committee of the British Thoracic Society. First randomised trial of treatments for pulmonary disease caused by M. avium-intracellulare, M. malmoense and M. xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol. Thorax 2001; 56: 16772.
  • 43
    Heifets L. Synergistic effects of rifampicin, streptomycin, ethionamide, and ethambutol on Mycobacterium intracellulare. Am. Rev. Respir. Dis. 1982; 125: 438.
  • 44
    Wallace RJ, Zhang Y, Brown BA, Dawson D, Murphy DT et al. Polyclonal Mycobacterium avium Complex infections in patients with nodular bronchiectasis. Am. J. Respir. Crit. Care Med. 1998; 158: 123544.
  • 45
    Semret M, Turenne CY, De Haas P, Collins DM, Behr MA. Differentiating host-associated variants of Mycobacterium avium by PCR for detection of large sequence polymorphisms. J. Clin. Microbiol. 2006; 44: 8817.
  • 46
    Huebner RE, Schein MF, Cauthen GM, Geiter LJ, Selin MJ et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am. Rev. Respir Dis. 1992; 145: 11606.
  • 47
    Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N et al. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin. Infect. Dis. 2006; 43: 15406.
  • 48
    Detjen AK, Keil T, Roll S, Hauer B, Mauch H et al. Interferon-gamma release assays improve the diagnosis of tuberculosis and nontuberculous mycobacterial disease in children in a country with a low incidence of tuberculosis. Clin. Infect. Dis. 2007; 45 (3): 3228.
  • 49
    Tobin-D'Angelo MJ, Blass MA, Del Rio C, Halvosa JS, Blumberg HM et al. Hospital water as a source of Mycobacterium avium complex isolates in respiratory specimens. J. Infect. Dis. 2004; 189: 98104.
  • 50
    Collins C, Yates M. Infection and colonisation by Mycobacterium kansasii and Mycobacterium xenopi: aerosols as a possible source? J. Infect. 1984; 8: 1789.
  • 51
    Wolinsky E. When is an infection disease? Rev. Infect. Dis. 1981; 3: 10257.
  • 52
    Rossman M. Colonization with Mycobacterium avium complex—an outdated concept. Eur. Respir. J. 1999; 13: 479.
  • 53
    Corbett E, Blumberg L, Churchyard G, Moloi N, Mallory K et al. Nontuberculous mycobacteria. Defining disease in a prospective cohort of South African miners. Am. J. Resp. Crit. Care Med. 1999; 160: 1521.
  • 54
    Hunter A, Campbell I, Jenkins P, Smith A. Treatment of pulmonary infections caused by the Mycobacterium avium–intracellulare complex. Thorax 1981; 36: 3269.
  • 55
    Yeager J, Raleigh J. Pulmonary disease due to M. intracellulare. Am. Rev. Respir. Dis. 1973; 108: 54752.
  • 56
    Prince D, Peterson D, Steiner R, Gottlieb J, Scott R et al. Infection with Mycobacterium avium complex in patients without predisposing conditions. N. Engl. J. Med. 1989; 321: 863.
  • 57
    Maekura R, Okuda Y, Hirotani A, Kitada S, Hiraga T et al. Clinical and prognostic importance of serotyping Mycobacterium avium-Mycobacterium intracellulare complex isolates in human immunodeficiency virus-negative patients. J. Clin. Microbiol. 2005; 43: 31508.
  • 58
    Kuroishi S, Nakamura Y, Hayakawa H, Shirai M, Nakano Y et al. Mycobacterium avium complex disease: prognostic implication of high-resolution CT findings. Eur. Respir. J. 2008; 32: 14752.
  • 59
    Kobashi YMT. Comparison of clinical features in patients with pulmonary Mycobacterium avium complex (MAC) disease treated before and after proposal for guidelines. J. Infect. Chemother. 2004; 10: 2530.
  • 60
    Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am. J. Respir. Crit. Care Med. 1997; 156: S125.
  • 61
    Subcommittee of the Joint Tuberculosis Committee of the British Thoracic Society. Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999. Thorax 2000; 55: 2108.
  • 62
    The Japanese Society for Tuberculosis. Treatment of nontuberculous mycobacteriosis. Kekkaku 1998; 73: 599605.
  • 63
    Jenkins PA, Campbell IA, Banks J, Gelder CM, Prescott RJ et al. Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy. Thorax 2008; 63: 62734.
  • 64
    Lam PK, Griffith DE, Aksamit TR, Ruoss SJ, Garay SM et al. Factors related to response to intermittent treatment of Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 12839.
  • 65
    Dautzenburg B, Piperno D, Diot P, Chantal T-P, Chauvin J-P. Clarithromycin in the treatment of Mycobacterium avium lung infections in patients without AIDS. Chest 1995; 107: 103540.
  • 66
    Wallace RJ, Brown BA, Griffith DE, Girard WM, Murphy DT. Clarithromycin regimens for pulmonary Mycobacterium avium complex. Am. J. Respir. Crit. Care Med. 1996; 153: 176672.
  • 67
    Griffith DE, Brown-Elliott BA, Langsjoen B, Zhang Y, Pan X et al. Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 2006; 174: 92834.
  • 68
    Griffith DE, Brown BA, Girard WM, Griffith BE, Couch LA et al. Azithromycin-containing regimens for treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 2001; 32: 154753.
  • 69
    Field S, Cowie R. Treatment of Mycobacterium avium-intracellulare complex lung disease with a macrolide, ethambutol, and clofazimine. Chest 2003; 124: 14826.
  • 70
    Griffith D, Brown-Elliott B, Girard W, Wallace R Jr. Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin. Infect. Dis. 1995; 21: 5948.
  • 71
    Griffith D, Brown-Elliott B, Wallace Jr R. Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus-negative patients who are receiving multidrug regiments for pulmonary Mycoabcterium avium complex disease. Clin. Infect. Dis. 1996; 23: 13212.
  • 72
    Kohno Y, Ohno H, Miyazaki Y, Higashiyama Y, Yanagihara K et al. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan. Antimicrob. Agents Chemother. 2007; 51: 40716.
  • 73
    Bermudez LE, Kofonoski P, Petrofsky M, Wu M, Inderfield CB et al. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J. Infect. Dis. 2003; 187: 197780.
  • 74
    Kobashi YMT, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir. Med. 2007; 101: 1308.
  • 75
    Hanak V, Kalra S, Aksamit TR, Hartman TE, Tazelaar HD et al. Hot tub lung: presenting features and clinical course of 21 patients. Respir. Med. 2006; 100: 61015.
  • 76
    Ahn C, Lowell J, Ahn S, Ahn S, Hurst G. Short-course chemotherapy for pulmonary disease caused by Mycobacterium kansasii. Am. Rev. Respir. Dis. 1983; 128: 104850.
  • 77
    The Research Committee of the British Thoracic Society. Mycobacterium kansasii pulmonary infection: a prospective study of the results of nine months of treatment with rifampicin and ethambutol. Thorax 1994; 49: 4425.
  • 78
    Wallace R, Dunbar D, Brown B, Onyi G, Dunlap R et al. Rifampin-resistant Mycobacterium kansasii. Clin. Infect. Dis. 1994; 18: 73643.
  • 79
    Griffith D, Brown-Elliott B, Wallace Jr R. Thrice-weekly clarithromycin-containing regimen for treatment of Mycobacterium kansasii lung disease: results of a preliminary study. Clin. Infect. Dis. 2003; 37: 117882.
  • 80
    Alcaide F, Calatayud L, Santin M, Martin R. Comparative in vitro activities of linezolid, telithromicin, clarithromicin, levofloxacin, moxafloxacin, and four conventional antimycobacterial drugs against Mycobacterium kansasii. Antimicrob. Agents Chemother. 2004; 48: 45625.
  • 81
    Schroder K, Juhlin I. Mycobacterium malmoense sp nov. Int. J. Syst. Bacteriol. 1977; 27: 2416.
  • 82
    Buchholz U, McNeil M, Keyes L, Good R. Mycobacterium malmoense infections in the United States; January 1993 through June 1995. Clin. Infect. Dis. 1998; 27: 5518.
  • 83
    Nakayama S, Fujii T, Kadota J, Sawa H, Hamage S et al. Pulmonary mycobacteriosis caused by rifampicin-resistant Mycobacterium szulgai. Intern. Med. 2000; 39: 30912.
  • 84
    Sanchez-Alarcos J, De Miguel-Diez J, Bonilla I, Sicilia J, Alvarez-Sala J. Pulmonary infection due to Mycobacterium szulgai. Respiration 2003; 70: 5336.
  • 85
    Gillespie SH, Billington O. Activity of moxifloxacin against mycobacteria. J. Antimicrob. Chemother. 1999; 44: 3935.
  • 86
    Faress J, McKinney L, Semann M, Byrd R Jr, Mehta J et al. Mycobacterium xenopi pneumonia in the southeastern United States. South. Med. J. 2003; 96: 5969.
  • 87
    Yew W, Kwan S, Wong P, Lee J. Ofloxacin and imipenem in the treatment of Mycobacterium fortuitum and Mycobacterium chelonae lung infections. Tubercle 1992; 71: 1313.
  • 88
    Yew W, Lau K, Tse W, Wong C. Imipenem in the treatment of lung infections due to Mycobacterium fortuitum and Mycobacterium chelonae. Clin. Infect. Dis. 1992; 15: 10467.
  • 89
    Wagner D, Young L. Nontuberculous mycobacterial infections: a clinical review. Infection 2004; 32: 25770.
  • 90
    The Research Committee of the British Thoracic Society. Pulmonary disease caused by Mycobacterium avium-intracellulare in HIV negative patients: five-year follow-up of patients receiving standardised treatment. Int. J. Tuberc. Lung Dis. 2002; 6: 62834.
  • 91
    Brown BA, Wallace R Jr, Griffith D, Girard W. Clarithromycin induced hepatotoxicity. Clin. Infect. Dis. 1995; 20: 10734.
  • 92
    Brown BA, Griffith DE, Girard WM, Levin J, Wallace RJ. Relationship of adverse events to serum drug levels in patients receiving high-dose azithromycin for mycobacterial lung disease. Clin. Infect. Dis. 1997; 24: 95864.
  • 93
    Griffith DE, Brown-Elliott BA, Shepherd S, McLarty J, Griffith L et al. Ethambutol ocular toxicity in treatment regimens for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 2005; 172: 2503.
  • 94
    Wallace R Jr, Brown BA, Griffith D, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-intracellulare infection. J. Infect. Dis. 1995; 171: 74750.
  • 95
    Kuper J, D'Aprile M. Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin. Pharmacokinet. 2000; 39: 20314.
  • 96
    Thompson C, Harrison S, Ashley J, Day K, Smith D. Randomised crossover study of the flutter device and the active cycle of breathing technique in non-cystic fibrosis bronchiectasis. Thorax 2002; 57: 4468.
  • 97
    Daviskas E, Anderson S, Eberl S, Bautovich HK, Bautovich G. Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am. J. Resp. Crit. Care Med. 1999; 159: 18438.
  • 98
    Kellett F, Redfern J, Niven R. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir. Med. 2005; 99: 2731.
  • 99
    Nelson K, Griffith D, Brown-Elliott B, Wallace R Jr. Results of operation in Mycobacterium avium-intracellulare lung disease. Ann. Thorac. Surg. 1998; 66: 32530.
  • 100
    Shiraishi Y, Nakajima Y, Takasuna K, Hanaoka T, Katsuragi N et al. Surgery for Mycobacterium avium complex lung disease in the clarithromycin era. Eur. J. Cardiothorac. Surg. 2002; 21: 31418.
  • 101
    Shiraishi Y, Fukushima K, Komatsu H, Kurashima A. Early pulmonary resection for localised Mycobacterium avium complex disease. Ann. Thorac. Surg. 1998; 66: 1836.
  • 102
    Watanabe A, Hasegawa N, Ishizaka A, Asakura K, Tzumi Y et al. Early pulmonary resection for Mycobacterium avium complex lung disease treated with macrolides and quinolones. Ann. Thorac. Surg. 2006; 81: 202630.
  • 103
    Shiraishi Y, Nakajima Y, Katsuragi N, Kurai M, Takahashi N. Pneumonectomy for nontuberculous mycobacterial infections. Ann. Thorac. Surg. 2004; 78: 399403.
  • 104
    Kitada S, Kobayashi K, Ichiyama S, Takakura S, Sakatani M et al. Serodiagnosis of Mycobacterium avium-Complex pulmonary disease using an enzyme immunoassay kit. Am. J. Respir. Crit. Care Med. 2008; 177: 7937.
  • 105
    Kwon YS, Kim EJ, Lee S-H, Suh GY, Chung MP et al. Decreased cytokine production in patients with nontuberculous mycobacterial lung disease. Lung 2007; 185: 33741.
  • 106
    Vankayalapati R, Wizel B, Samten B, Griffith D, Shams H et al. Cytokine profiles in immunocompetent persons infected with Mycobacterium avium complex. J. Infect. Dis. 2001; 183: 47884.
  • 107
    Greinert U, Schlaak M, Rusch-Gerdes S, Flad H, Ernst M. Low in vitro production of interferon-gamma and tumor necrosis factor alpha in HIV-seronegative patients with pulmonary disease caused by nontuberculous mycobacteria. J. Clin. Immunol. 2000; 20: 44552.
  • 108
    Chatte G, Panteix G, Perrin-Fayolle M, Pacheco Y. Aerosolized interferon gamma for Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 1995; 152: 10946.
  • 109
    Silva R, Pais T, Appelberg R. Evaluation of IL-12 in immunotherapy and vaccine design in experimental Mycobacterium avium infections. J. Immunol. 1998; 161: 557885.
  • 110
    Doherty T, Sher AIL-12 promotes drug-induced clearance of Mycobacterium avium infection in mice. J. Immunol. 1998; 160: 542835.
  • 111
    Brown-Elliot BA, Wallace R Jr, Blinkhorn R, Crist C, Mann L. Successful treatment of disseminated Mycobacterium chelonae infection with linezolid. Clin. Infect. Dis. 2001; 33: 143344.
  • 112
    Yang S, Hsueh P, Lai H, Teng LJ, Huang LM et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob. Agents Chemother. 2003; 47: 195862.
  • 113
    Brown-Elliot B, Crist C, Mann L, Wilson R, Wallace R Jr. In vitro activity of linezolid against slowly growing nontuberculous mycobacteria. Antimicrob. Agents Chemother. 2003; 47: 17368.
  • 114
    Wallace R Jr, Brown-Elliot BA, Crist C, Mann L, Wilson R. Comparison of the in vitro activity of the glycylcycline tigecycline (formerly GAR-936) with those of tetracycline, minocycline and doxycycline against isolates of nontuberculous mycobacteria. Antimicrob. Agents Chemother. 2002; 46: 31647.
  • 115
    Huitric E, Verhasselt P, Andries K, Hoffner S. In vitro antimycobacterial spectrum of a diarylquinolone ATP synthase inhibitor. Antimicrob. Agents Chemother. 2007; 51: 42024.
  • 116
    Hickey A, Lu D, Ashley E, Stout J. Inhaled azithromycin therapy. J. Aerosol Med. 2006; 19: 5460.
  • 117
    Davis K, Kao P, Jacobs S, Ruoss S. Aerosolized amikacin for treatment of Mycobacterium avium infections: an observational case series. BMC Pulm. Med. 2007; 7: 2.